Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK2 | P24941 | 6/20 | 0.52 |
| ▸ | CCNE1 | P24864 | 5/20 | 0.52 |
| ▸ | CDK9 | P50750 | 3/20 | 0.52 |
| ▸ | CCNT1 | O60563 | 2/20 | 0.52 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.44 |
| ▸ | CCNA1 | P78396 | 1/20 | 0.44 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | MPI | P34949 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | PARP1 | P09874 | 3/20 | 0.41 |
| ▸ | JAK2 | O60674 | 2/20 | 0.41 |
| ▸ | JAK1 | P23458 | 2/20 | 0.41 |
| ▸ | TYK2 | P29597 | 2/20 | 0.41 |
| ▸ | JAK3 | P52333 | 2/20 | 0.41 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.39 |
| ▸ | ABL1 | P00519 | 1/20 | 0.39 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1633421 | 0.85 | MAP3K5 (0.49) | CDK2CCNE1MAPTMEN1KMT2A | |
| SCHEMBL1634323 | 0.80 | JAK2 (0.47) | CDK2CCNE1PTK2JAK2JAK1 | |
| SCHEMBL1634286 | 0.79 | AURKA (0.53) | CDK2CCNE1PTK2JAK2JAK1 | |
| SCHEMBL1633381 | 0.79 | PTK2 (0.54) | CDK2PTK2JAK2JAK1TYK2 | |
| SCHEMBL1633395 | 0.78 | CDK2 (0.49) | CDK2CCNE1CDK9CCNT1CCNA2 | |
| SCHEMBL1632354 | 0.77 | PKM (0.43) | CDK2CCNE1CDK9CCNT1JAK2 | |
| SCHEMBL1632814 | 0.77 | CDK2 (0.52) | CDK2CCNE1CDK9CCNT1CCNA2 | |
| SCHEMBL1631342 | 0.76 | CDK2 (0.45) | CDK2CCNE1CDK9CCNT1CCNA2 | |
| SCHEMBL1632891 | 0.74 | JAK2 (0.48) | CDK2CCNE1CDK9CCNA2MEN1 | |
| SCHEMBL1634669 | 0.73 | BRD4 (0.49) | CDK2CCNE1CDK9CCNT1CCNA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7932262-B2 | Quinazolines for PDK1 inhibition | NOVARTIS AG (CH) | 2011-04-26 | — | — | US | disclosed |
| US-7932262-B2 | Quinazolines for PDK1 inhibition | NOVARTIS AG (CH) | 2011-04-26 | — | — | US | disclosed |
| US-7932262-B2 | Quinazolines for PDK1 inhibition | NOVARTIS AG (CH) | 2011-04-26 | — | — | US | disclosed |
| US-20100048561-A1 | QUINAZOLINES FOR PDK1 INHIBITION | NOVARTIS VACCINES & DIAGNOSTICS, INC. (US) | 2010-02-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100048561-A1 | QUINAZOLINES FOR PDK1 INHIBITION | PDK1, PDK2, PDK3 | CDK2 29/4885CCNE1 637/4885CDK9 67/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.